TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8624760

Group type: EXPERIMENTAL
Intervention: ZDV (Zidovudine)
Number of subjects: 245

Group type: COMPARATOR
Intervention: ddI (Didanosine)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Imputation methods (carrying forward last observed count, regression models, decline assumption)
Number of subjects: 245
Study: 1892239

Group type: EXPERIMENTAL
Intervention: CLS 2210
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison group (no CLS 2210)
Number of subjects: 100
Study: 6223484

Group type: EXPERIMENTAL
Intervention: Rydell nail
Number of subjects: 134

Group type: COMPARATOR
Intervention: Hook-pins
Number of subjects: 134
Study: 30815706

Group type: EXPERIMENTAL
Intervention: Enhanced client-centered approach
Number of subjects: 237

Group type: COMPARATOR
Intervention: Not receiving enhanced client-centered approach
Number of subjects: 237

Group type: COMPARATOR
Intervention: Home rehabilitation (control group)
Number of subjects: 237
Study: 30204574

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 55
Study: 26977860

Group type: EXPERIMENTAL
Intervention: Honey dressing
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional dressing
Number of subjects: 52
Study: 25135803

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention in a monitoring program for CKD patients, including daily follow-up and recommendations for dose adjustments of nephrotoxic drugs.
Number of subjects: 249

Group type: COMPARATOR
Intervention: Control group with standard monitoring of renal function at admission and discharge without pharmacist intervention.
Number of subjects: 249
Study: 21903744

Group type: EXPERIMENTAL
Intervention: CardioFit Internet-based expert system
Number of subjects: 223

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 223
Study: 21186908

Group type: EXPERIMENTAL
Intervention: Priming (implicit memory)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-system model prediction
Number of subjects: 0
Study: 17667566

Group type: EXPERIMENTAL
Intervention: Procalcitonin
Number of subjects: 100

Group type: COMPARATOR
Intervention: C‐reactive protein
Number of subjects: 100

Group type: COMPARATOR
Intervention: White blood cell count
Number of subjects: 100

Group type: COMPARATOR
Intervention: Interleukins 6 and 8
Number of subjects: 100
Study: 16221223

Group type: EXPERIMENTAL
Intervention: Plasma ADMA concentration
Number of subjects: 93
Study: 11834952

Group type: COMPARATOR
Intervention: Recombinant human nerve growth factor (placebo-controlled)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 236
Study: 10195377

Group type: EXPERIMENTAL
Intervention: Fructose ingestion
Number of subjects: 13

Group type: COMPARATOR
Intervention: Glucose ingestion
Number of subjects: 13
Study: 7756047

Group type: EXPERIMENTAL
Intervention: Bisphosphonate therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of pre-treatment alkaline phosphatase and alkaline phosphatase half-life
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of pre-treatment hydroxyproline and hydroxyproline half-life
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement of half-lives of markers of bone turnover
Number of subjects: 0
Study: 2319516

Group type: EXPERIMENTAL
Intervention: Intravenous 'minipulse' (100 mg) methylprednisolone (MP) therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard pulse (1000 mg) methylprednisolone (MP) therapy
Number of subjects: 36
Study: 583022

Group type: EXPERIMENTAL
Intervention: 15 mg treptilamine i.v.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 40 mg treptilamine p.o.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31866190

Group type: EXPERIMENTAL
Intervention: Dantrolene (1 cap, 25 mg three times daily, or two times daily if not tolerable)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 300
Study: 31461575

Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy
Number of subjects: 213
Study: 28109874

Group type: EXPERIMENTAL
Intervention: Durable‐polymer zotarolimus‐eluting stent
Number of subjects: 2999

Group type: COMPARATOR
Intervention: Biodegradable‐polymer biolimus‐eluting stent
Number of subjects: 2999
Study: 25523054

Group type: EXPERIMENTAL
Intervention: r-tPA plus eptifibatide
Number of subjects: 85
Study: 24524031

Group type: EXPERIMENTAL
Intervention: Haloperidol 2 mg
Number of subjects: 98

Group type: COMPARATOR
Intervention: Sterile water (placebo)
Number of subjects: 98
Study: 22159768

Group type: EXPERIMENTAL
Intervention: NutriAlz program (intervention group)
Number of subjects: 946

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 946
Study: 18707785

Group type: EXPERIMENTAL
Intervention: Low boost dose of 10 Gy
Number of subjects: 251

Group type: COMPARATOR
Intervention: High boost dose of 26 Gy
Number of subjects: 251
Study: 16937967

Group type: EXPERIMENTAL
Intervention: OSt (resisted-sprint training)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: OSp (assisted-sprint training)
Number of subjects: 37

Group type: COMPARATOR
Intervention: C (control group)
Number of subjects: 37
Study: 15265250

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 2413

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg
Number of subjects: 2413
Study: 11735866

Group type: EXPERIMENTAL
Intervention: 10-day course of i.v. ampicillin, gentamicin sulfate, and clindamycin (n = 10)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Short course of i.v. ampicillin, gentamicin, and clindamycin followed by p.o. amoxicillin and clavulanate potassium plus metronidazole (n = 16)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Conversion to oral therapy
Number of subjects: 26
Study: 11367661

Group type: EXPERIMENTAL
Intervention: Neiyixiao Recipe (NYXR)
Number of subjects: 103

Group type: COMPARATOR
Intervention: danazol (Control)
Number of subjects: 103
Study: 8172790

Group type: EXPERIMENTAL
Intervention: Vinorelbine (NVB) 30 mg/m2/week
Number of subjects: 231

Group type: COMPARATOR
Intervention: Vinorelbine (NVB) 30 mg/m2/week plus Cisplatin (DDP) 80 mg/m2/3 weeks
Number of subjects: 231
Study: 3266254

Group type: EXPERIMENTAL
Intervention: Questionnaire-first group (completed questionnaire before biochemical validation)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Pipeline-first group (samples collected before completing questionnaire)
Number of subjects: 160
Study: 31623096

Group type: EXPERIMENTAL
Intervention: Combined warm up (CWU)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Global warm up (GWU)
Number of subjects: 28
Study: 29033296

Group type: EXPERIMENTAL
Intervention: Prochlorperazine and diphenhydramine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Ketamine and ondansetron
Number of subjects: 54
Study: 26721229

Group type: EXPERIMENTAL
Intervention: Knee joint mobilization (6 minutes)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manual cutaneous input only (control)
Number of subjects: 40
Study: 25632741

Group type: EXPERIMENTAL
Intervention: Salvia Miltiorrhiza (1 g each time, three times per day till one month after PCI)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 52
Study: 22309178

Group type: EXPERIMENTAL
Intervention: Honey mouthwash
Number of subjects: 66

Group type: COMPARATOR
Intervention: 0.2% Chlorhexidine gluconate rinse
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Honey rinse
Number of subjects: 66

Group type: COMPARATOR
Intervention: 0.2% Chlorhexidine rinse
Number of subjects: 66

Group type: COMPARATOR
Intervention: Saline rinse
Number of subjects: 66
Study: 19908937

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17392122

Group type: EXPERIMENTAL
Intervention: Black rice pigment fraction (BRF) supplementation (10 grams for 6 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: White rice pigment fraction (WRF) supplementation (10 grams for 6 months)
Number of subjects: 60
Study: 15124679

Group type: EXPERIMENTAL
Intervention: Treosulfan/fludarabine (3 x 10 g/m2 of treosulfan with 5 x 30 mg/m2 of fludarabine)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Treosulfan (escalated from 3 x 10 to 3 x 12 and 3 x 14 g/m2)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Treosulfan
Number of subjects: 55
Study: 10865808

Group type: EXPERIMENTAL
Intervention: recombinant growth hormone (rhGH) for the first six months
Number of subjects: 23

Group type: COMPARATOR
Intervention: placebo for the first six months
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: recombinant growth hormone (rhGH) for the second six months
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: recombinant growth hormone (rhGH) for both groups in the second six months
Number of subjects: 23
Study: 9277247

Group type: EXPERIMENTAL
Intervention: Visual aids alone
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Visual aids plus an Advanced Organizer
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no visual aids)
Number of subjects: 78
Study: 8222667

Group type: EXPERIMENTAL
Intervention: Antihypertensive drug treatment
Number of subjects: 4736

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4736
Study: 3512394

Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Porcine insulin
Number of subjects: 30
Study: 3446162

Group type: EXPERIMENTAL
Intervention: Low pH intravenous immunoglobulin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard intravenous immunoglobulin
Number of subjects: 18
Study: 30475043

Group type: EXPERIMENTAL
Intervention: Web-based training program on pediatric medical traumatic stress and trauma-informed care (15-min online training program)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no training initially)
Number of subjects: 71
Study: 28620924

Group type: EXPERIMENTAL
Intervention: Midazolam premedication
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Midazolam + Digital Video-Disk
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Digital Video-Disk alone
Number of subjects: 135

Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 135
Study: 25496615

Group type: EXPERIMENTAL
Intervention: Postnatal psychoeducation programme
Number of subjects: 122

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 122
Study: 23347874

Group type: EXPERIMENTAL
Intervention: Training and support, financial reimbursement, and internet-based counselling
Number of subjects: 120

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 120
Study: 21649612

Group type: EXPERIMENTAL
Intervention: Tetracycline (500 mg/day × 14 days/month × 3 months)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 18022183

Group type: EXPERIMENTAL
Intervention: Explaining to mom
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Explaining to themselves
Number of subjects: 54

Group type: COMPARATOR
Intervention: Repeating the solutions
Number of subjects: 54
Study: 16808575

Group type: EXPERIMENTAL
Intervention: Forsus Nitinol Flat Spring (FNFS)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Jasper Jumper (JJ)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 15296685

Group type: EXPERIMENTAL
Intervention: Listening to classical music
Number of subjects: 75

Group type: COMPARATOR
Intervention: Silence (Control)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Listening to jazz or pop music
Number of subjects: 75
Study: 10862530

Group type: EXPERIMENTAL
Intervention: Hypoxic training
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normoxic training
Number of subjects: 34
Study: 9242843

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 229
Study: 8290450

Group type: EXPERIMENTAL
Intervention: Povidone-iodine (PVP-I) ointment
Number of subjects: 129

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 129
Study: 3771765

Group type: EXPERIMENTAL
Intervention: Antimicrobial laparotomy drapes with 3-(trimethoxysilyl)propyldimethyloctadecyl ammonium chloride
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (non-antimicrobial segments of the drape)
Number of subjects: 110
Study: 30222643

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) preparation
Number of subjects: 43

Group type: COMPARATOR
Intervention: Fasting only (FO) preparation
Number of subjects: 43
Study: 29618327

Group type: EXPERIMENTAL
Intervention: Young & Active web-based intervention to increase physical activity
Number of subjects: 21
Study: 27003272

Group type: EXPERIMENTAL
Intervention: Corticosteroids + Facial Neuromuscular Training (C + FNT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Facial Neuromuscular Training (FNT)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 73
Study: 25538086

Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I (hsTnI) assay (Erenna, 99th percentile 9 pg/ml)
Number of subjects: 1807
Study: 24073978

Group type: EXPERIMENTAL
Intervention: Donepezil 23 mg/day
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg/day
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: SIB-8
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Full SIB
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Both SIB scales
Number of subjects: 1400
Study: 20493430

Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg
Number of subjects: 308
Study: 18179495

Group type: EXPERIMENTAL
Intervention: Enhanced counseling and support (six sessions of individual and family counseling, support group participation, and continuous availability of ad hoc telephone counseling)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 406
Study: 16854276

Group type: EXPERIMENTAL
Intervention: CHB patients
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CHB patients with HBV DNA > 10^7 copies/ml
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Convalescent phase
Number of subjects: 120

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 120
Study: 12727933

Group type: EXPERIMENTAL
Intervention: Replacement-dose r‐metHuLeptin during fasting
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low-dose r‐metHuLeptin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Baseline fed state
Number of subjects: 8
Study: 10733492

Group type: EXPERIMENTAL
Intervention: 6 cycles of MOPP/ABV
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: 6 cycles of MOPP/ABV plus RTx
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: 8 cycles of ABVPP
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: 6 cycles of ABVPP plus RTx
Number of subjects: 559

Group type: COMPARATOR
Intervention: Chemotherapy (CTx)
Number of subjects: 559

Group type: COMPARATOR
Intervention: Radiotherapy (RTx)
Number of subjects: 559

Group type: COMPARATOR
Intervention: Chemotherapy (CTx) after MOPP/ABV
Number of subjects: 559

Group type: COMPARATOR
Intervention: Radiotherapy (RTx) after MOPP/ABV
Number of subjects: 559

Group type: COMPARATOR
Intervention: Chemotherapy (CTx) after ABVPP
Number of subjects: 559

Group type: COMPARATOR
Intervention: Radiotherapy (RTx) after ABVPP
Number of subjects: 559
Study: 8958889

Group type: EXPERIMENTAL
Intervention: Adenosine infusion at 20-80 micrograms/kg/min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Adenosine infusion with oxygen administration
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Adenosine infusion
Number of subjects: 8
Study: 1550279

Group type: EXPERIMENTAL
Intervention: isoflurane with 70% N2O in oxygen (O2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: isoflurane in an air/O2 mixture
Number of subjects: 50
Study: 2868581

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg at bedtime for 6 months
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg at bedtime for 12 months
Number of subjects: 344

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 344

Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 344
Study: 31069549

Group type: EXPERIMENTAL
Intervention: Modified radical hysterectomy (mRH)
Number of subjects: 1335

Group type: COMPARATOR
Intervention: Simple hysterectomy (SH)
Number of subjects: 1335
Study: 28639216

Group type: EXPERIMENTAL
Intervention: 200 µg selexipag (Treatment A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4 paediatric tablets of 50 µg selexipag (Treatment B)
Number of subjects: 0
Study: 27676259

Group type: EXPERIMENTAL
Intervention: ICU communication facilitator
Number of subjects: 135
Study: 24412554

Group type: EXPERIMENTAL
Intervention: 500 mg Nigella sativa L. seeds (NS) once daily for four weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: 500 mg placebo once daily for four weeks
Number of subjects: 48
Study: 24568073

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (635 mg EPA, 195 mg DHA)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo (olive oil capsules)
Number of subjects: 103
Study: 19551236

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 707
Study: 17227907

Group type: EXPERIMENTAL
Intervention: 37.5 mg of venlafaxine (low‐dose study)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 75 mg of venlafaxine (high‐dose study)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 15138687

Group type: EXPERIMENTAL
Intervention: Physical activity counselling (n=35)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (n=35)
Number of subjects: 70
Study: 11593906

Group type: EXPERIMENTAL
Intervention: Hormonal treatment for localized disease (n=223)
Number of subjects: 642

Group type: COMPARATOR
Intervention: Primary treatment with radiotherapy (n=75) or radical prostatectomy (n=2) +/- hormonal treatment (n=77)
Number of subjects: 642
Study: 9442158

Group type: EXPERIMENTAL
Intervention: Lactate measurements
Number of subjects: 341

Group type: COMPARATOR
Intervention: pH analysis
Number of subjects: 341
Study: 7913949

Group type: EXPERIMENTAL
Intervention: Magnesium aspartate (15 mmol/day for 8 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (8 weeks)
Number of subjects: 39
Study: 2656133

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltaren)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Papaverine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diclofenac sodium (Voltaren) for low back pain (LBP)
Number of subjects: 60
Study: 31127284

Group type: EXPERIMENTAL
Intervention: Symptom-based screening
Number of subjects: 1017

Group type: COMPARATOR
Intervention: TST-based screening
Number of subjects: 1017
Study: 30113350

Group type: EXPERIMENTAL
Intervention: Ketamine infusion (bolus 0.2 mg/kg over 30 min followed by 0.12 mg/kg/h for 24 h)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Ketamine infusion (in opioid-naïve patients)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo (in opioid-naïve patients)
Number of subjects: 129
Study: 28485415

Group type: EXPERIMENTAL
Intervention: Prebiotic mix in yogurt (one yogurt per day for 12 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (yogurt without prebiotic mix)
Number of subjects: 24
Study: 26605505

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted atazanavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Ritonavir-boosted atazanavir (ATV/r) plus raltegravir (RAL)
Number of subjects: 109
Study: 25181784

Group type: EXPERIMENTAL
Intervention: Action plan intervention for self-management
Number of subjects: 19
Study: 22686416

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 12537

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 12537
Study: 20634623

Group type: EXPERIMENTAL
Intervention: Forced air warmer applied for 45-90 min before surgery
Number of subjects: 40
Study: 17617382

Group type: EXPERIMENTAL
Intervention: Intranasal application of 24 IU oxytocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16651205

Group type: EXPERIMENTAL
Intervention: Testim 1% (5 g)
Number of subjects: 48

Group type: COMPARATOR
Intervention: AndroGel 1% (5 g)
Number of subjects: 48
Study: 12147926

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telmisartan and Valsartan
Number of subjects: 0
Study: 9820705

Group type: EXPERIMENTAL
Intervention: Antithrombin III (AT III) treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9502783

Group type: EXPERIMENTAL
Intervention: L-2-Oxothiazolidine-4-carboxylic acid (OTC) 4.5 g
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 1662578

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (0.6 ng/min)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (1.8 ng/min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (Saline)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Angiotensin II
Number of subjects: 14
Study: 6922470

Group type: EXPERIMENTAL
Intervention: Nursing social support program
Number of subjects: 47

Group type: COMPARATOR
Intervention: Medication clinic
Number of subjects: 47
Study: 30894279

Group type: EXPERIMENTAL
Intervention: serlopitant, 5 mg, orally once daily for 8 weeks
Number of subjects: 128

Group type: COMPARATOR
Intervention: placebo, orally once daily for 8 weeks
Number of subjects: 128
Study: 27930386

Group type: EXPERIMENTAL
Intervention: GCSF 300 μg twice daily for 5 days plus standard medical therapy (SMT)
Number of subjects: 253

Group type: COMPARATOR
Intervention: SMT alone
Number of subjects: 253
Study: 25413483

Group type: EXPERIMENTAL
Intervention: Water immersion technique
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Cap-fitted colonoscopy
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 1005